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Hip2, a ubiquitin conjugating enzyme, is involved in the suppression of cell death. The present study
revealed that Hip2 regulates the stability of the apoptotic and cell cycle regulator cyclin B1. Hip2 was
found to interact with cyclin B1 to promote its degradation through the ubiquitin proteasome path-
way. As a result, Hip2 signiﬁcantly blocked cell death induced by the cyclin B1 protein, suggesting
that Hip2 is involved in the regulation of cyclin B1-mediated cell death.
Structured summary:
MINT-8045218, MINT-8045231: Hip2 (uniprotkb:P61086) physically interacts (MI:0915) with cyclin-B1
(uniprotkb:P14635) by pull down (MI:0096)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction speciﬁc protein substrates. The polyubiquitylated proteins are rap-E2-25 K/Hip2 is a ubiquitin conjugating enzyme (E2) that inter-
acts with huntingtin, a protein linked to Huntington’s disease [1],
and is highly expressed in the frontal cortex and striatum. The
Hip2 protein also mediates amyloid-b peptide (Ab) neurotoxicity,
which is associated with the neurodegeneration of Alzheimer’s dis-
ease (AD) [2]. The Hip2 gene has a high similarity to the UBC-1, -4,
and -5 genes of Saccharomyces cerevisiae [3]. The Hip2 protein is
also related to the APC/C (anaphase-promoting complex/cyclo-
some)-dependent assembly of K-48 linked polyubiquitin chains
in mammalian cells [4]. Interestingly, Hip2 is thought to play an
important role in the synthesis of K-48 linked multi-ubiquitin
chains in the absence of E3 ligases [5].
The ubiquitin proteasome system is involved in regulation of
several cellular processes in eukaryotic cells and its function is
mediated by the activity of three enzymes, a ubiquitin-activating
enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin
ligase (E3) [6,7]. The attachment of ubiquitin molecules to a target
protein proceeds through an initial step that involves the forma-
tion of a thiol ester bond between the C-terminal glycine of
ubiquitin and a cysteine residue of E1. In the second step, the
activated ubiquitin is delivered to a conserved cysteine residue of
the ubiquitin-conjugating enzyme E2. In the last step, the ubiquitin
ligase E3 binds to the ubiquitin-conjugating enzyme and targetschemical Societies. Published by Eidly degraded by 26S proteasome-mediated pathways [8,9].
Cyclin B1 regulates the entry into mitosis in vertebrates [10].
The concentration of cyclin B1 rises in the S phase and peaks dur-
ing late G2-M phase [11]. Cyclin B1 is degraded at the metaphase-
anaphase transition by a multisubunit complex called APC/C
[12,13]. Cyclin B1 is also a key regulator of apoptosis in various cell
types [14,15].
The present study shows the interaction between Hip2 and cy-
clin B1 and the regulation of cyclin B1 stability by the ubiquitin
proteasome pathway. Furthermore, the present results show that
Hip2 inhibits cell death induced by cyclin B1, suggesting that
Hip2 might be involved in the regulation of cyclin B1-induced
apoptosis.
2. Materials and methods
2.1. Plasmids, transfections and cell culture
Full length cDNAs encoding Hip2 were ampliﬁed through the
polymerase chain reaction (PCR) and cloned into the pCMV-HA
vector digested with HindIII and EcoRI. pCMV-Flag-5bHip2
(S86Y), containing a core domain mutation (S86Y) that selectively
inactivates polyubiquitin chain synthesis catalyzed by Hip2, was
kindly provided by Y.K. Jung (University of Seoul, Seoul) [2,5].
Hip2 (S86Y) was subcloned into the pCMV-HA vector digested with
HindIII and EcoRI. The pBluescriptII Hip2 construct was subcloned
into pcDNA-GST digested with BamH1 and EcoRI. Full lengthlsevier B.V. All rights reserved.
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quently cloned into pCMV-His C digested with XbaI and ApaI.
HEK293 and HEK293T cells were maintained in DMEM medium
supplemented with 8% fetal bovine serum (FBS), streptomycin
(100 lg/ml), and penicillin (100 U/ml) (Gibco-BRL). HCT116 cells
were maintained in McCoy’s 5A medium supplemented with 10%
fetal bovine serum (FBS), streptomycin (100 lg/ml), and penicillin
(100 U/ml) (Welgene). The PEI method was used according to the
manufacturer’s instructions (Sigma) to transfect various plasmids
into HEK293 or HEK293T cells. HCT116 cells were transfected with
various plasmids by using the TurboFect method (Fermentas).
2.2. Co-immunoprecipitation and immunoblot experiments
HEK293T cells were co-transfected with GST-tagged Hip2 and
His-tagged cyclin B1 constructs. Co-immunoprecipitation experi-
ments and immunoblot analysis were performed as described pre-
viously [16].
2.3. RNAi
The following sequences were cloned in this study: shHip2, 50-
TGGAATCAGACTGAATTAATTCAAGAGATTAATTCAGTCTGATTCCATT
TTTT-30; and shGFP, 50-GCT GAC CCT GAA GTT CAT CTT CAA GAG
AGA TGA ACT TCA GGG TCA GCT TTT TT-30. The pSilencer 1.0-U6
vector (Ambion) encoding the hairpin RNAs was transfected into
HEK293 cells or HCT116 cells using the PEI method (Sigma).
2.4. Polyubiquitination assay
HCT116 cells were transiently transfected with pcDNA/HA-Hip2
or pcDNA/HA-Hip2 (S86Y) and pcDNA/Xpress-Ub. After 36 h, the
transfected cells were treated with or without the proteasome
inhibitor MG-132 (10 lM) for an additional 5 h. The cells were
lysed and the lysate supernatants were pre-cleared with proteinFig. 1. Hip2 regulates the stability of the cyclin B1 protein. (A) HEK293 cells were trans
harvested, and equal amounts of protein (20 lg) were separated by SDS–PAGE and tran
cyclin B1 antibodies. HA and actin were used as loading controls. (B) HEK293 cells were
under the same conditions as in (A) and lysates were subjected to immunoblot analysis
control vector. The cells were treated with 100 lg/ml cycloheximide (CHX) and incubated
a membrane, and then probed with anti-cyclin B1 antibodies. The membrane was subseq
intensities of immunoblot results shown in the panel C was measured using Multi Gauge
Hip2 was already reduced, it was normalized with that of time 0 h cyclin B1 in the abseG-sepharose (GE Healthcare) for 1 h at 4 C. Immunoprecipitation
was carried out overnight at 4 C with anti-cyclin B1 antibodies.
After washing four times with NETN buffer, the precipitated pro-
teins were analyzed by immunoblotting against anti-ubiquitin
antibodies.
2.5. Degradation assay
To measure the stability of the cyclin B1 proteins in HEK293
cells, these cells were transiently transfected with pcDNA/HA-
Hip2 or control vector. After a 24 h transfection, the cells were
treated with 100 lg/ml of cycloheximide (CHX) for various time
periods. The cell lysates were subjected to SDS–PAGE, transferred
to a membrane, and then probed with anti-cyclin B1 and anti-b-ac-
tin antibodies.
2.6. Flow cytometry analysis
To measure apoptosis using the annexin V-FITC apoptosis kit
(BD Biosciences). HCT116 cells were co-transfected with HA-
tagged Hip2 and His-tagged cyclin B1 constructs. After 48 h, the
cells were harvested and washed with PBS. FITC-conjugated annex-
in V (1 lg/ml) and propidium iodide (50 lg/ml) were added to the
cells and incubated for 30 min at room temperature. Analyses were
done using a FACScan ﬂow cytometer (BD Biosciences).
3. Results and discussion
3.1. Hip2 regulates the stability of the cyclin B1 protein
The results of the present study unexpectedly showed that the
stability of cyclin B1 was affected by the presence of Hip2. To con-
ﬁrm this ﬁnding, human embryonic kidney (HEK) 293 cells were
transiently transfected with plasmid constructs containing
pcDNA/HA-Hip2 or a negative control vector. The transfected cellsiently transfected with control vector or pcDNA/HA-Hip2. After 24 h, the cells were
sferred to nitrocellulose membranes. Cyclin B1 was detected using polyclonal anti-
transfected with control shRNA or Hip2 shRNA. After 36 h, the cells were harvested
. (C) HEK293 cells were transiently transfected with pcDNA/HA-Hip2 or a negative
for the indicated times. The cell lysates were subjected to SDS–PAGE, transferred to
uently probed with anti-HA and anti-actin antibodies. (D) Quantiﬁcation of the band
image analysis software. Since the amount of time 0 h cyclin B1 in the presence of
nce of Hip2. Values represent means ± S.D. of three independent experiments.
Fig. 2. Hip2 interacts with the cyclin B1 protein. HEK293T cells were transiently co-
transfected with either pcDNA/GST or pcDNA/GST-Hip2. After 36 h, the cell lysates
were precipitated with glutathione sepharose beads for 3 h at 4 C. The bound
proteins were eluted and subjected to immunoblot analysis against polyclonal anti-
cyclin B1 antibodies.
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sis. In the presence of Hip2, the expression level of the cyclin B1
protein was signiﬁcantly decreased, as shown in Fig. 1A.
To further conﬁrm the effect of Hip2 on decreasing the stability
of cyclin B1, shRNA experiments were performed to knock down
Hip2. HEK293 cells were transiently transfected with Hip2 shRNA
or control shRNA, and the expression level of cyclin B1 was deter-
mined by immunoblot analysis. As expected, cyclin B1 expression
levels were increased in cells depleted of the Hip2 protein (Fig. 1B).
The effect of Hip2 on the destabilization of cyclin B1 was also
examined in the presence of cycloheximide (CHX) to block de novo
protein synthesis in eukaryotic cells. HEK293 cells were transiently
transfected with pcDNA/HA-Hip2 or a negative control vector for
24 h, followed by treatment with CHX. The cells were harvested
at the times indicated in Fig. 1C, and immunoblot analysis was per-
formed to determine the levels of the cyclin B1 protein. Band inten-
sities were measured using Multi Gauge image analysis software
(Fig. 1D). In the presence of CHX, the degradation of cyclin B1 oc-
curred at a faster rate in cells transfected with Hip2 than in cells
transfected with negative control vector. The expression level of
Hip2 also was quickly reduced in the presence of CHX, indicating
that the turnover rate of Hip2 is fast. Taken together, these results
demonstrate that Hip2 signiﬁcantly destabilizes cyclin B1.
Next, using nocodazole, we synchronized cells to assess the sta-
bility of cyclin B1 during the metaphase-anaphase transition in the
presence of Hip2. Cells treated with nocodazole cannot form meta-
phase spindles due to deﬁcient polymerization of microtubules.
We transiently transfected HEK293 cells with pcDNA/HA-Hip2 or
control vector. The cells were harvested at the times indicated in
Supplementary Fig. S1, and the expression level of cyclin B1 was
determined by immunoblot analysis. Cyclin B1 was more reduced
in the presence Hip2 than in the absence of Hip2. However, these
results did not provide further information whether Hip2 is in-
volved in cell cycle progression by regulating cyclin B1 stability.
The cyclin B1-cdc2 kinase complex phosphorylates a variety of
target substrates, which is required for mitotic entry [17]. We
investigated whether the destability of cyclin B1 in the presence
of Hip2 affects the activity of the cdc2 kinase. HEK293 cells were
transfected with pcDNA/HA-Hip2 or a negative control vector
and cdc2 kinase assays were performed using histone H1 substrate.
As shown in Supplementary Fig. S2, the activity of the cdc2 kinase
was more decreased in cells overexpressing Hip2 than in those
transfected with control vector, suggesting that Hip2 might be in-
volved in the G2-M transition by regulating cyclin B1 stability.
3.2. Hip-2 interacts with and ubiquitinates cyclin B1
Previous studies indicated that cyclin B1 is degraded through
the ubiquitin proteasome pathway [14]. To examine whether the
Hip2-mediated destabilization of cyclin B1 is also associated with
the ubiquitin proteasome pathway, the potential role of the ubiq-
uitin-conjugating enzyme Hip2 in the degradation of cyclin B1
was investigated by ﬁrst examining whether Hip2 interacts with
the cyclin B1 protein. HEK293T cells were transiently cotransfected
with plasmid constructs containing either pcDNA/GST or pcDNA/
GST-Hip2, and pcDNA/HisC-cyclin B1. The cell extracts were incu-
bated with glutathione sepharose beads for 3 h. The bound pro-
teins were eluted, subjected to SDS–PAGE, and analyzed by
immunoblotting with anti-cyclin B1 antibodies. As shown in Sup-
plementary Fig. S3, the His-tagged cyclin B1 protein interacted
with GST-Hip2 in the in vivo coimmunoprecipitation experiment.
The interaction between these two proteins was further
conﬁrmed with endogenous cyclin B1 by transiently transfecting
HEK293T cells with pcDNA/GST or pcDNA/GST-Hip2. The cell ex-
tracts were incubated with glutathione sepharose beads for 3 h.
The bound proteins were eluted and subjected to immunoblotanalysis with cyclin B1 antibodies. As shown in Fig. 2 endogenous
cyclin B1 interacts with the Hip2 protein.
Next, we further investigated whether the interaction between
Hip2 and cyclin B1 is also associated with cdc27, which is a mem-
ber of APC/C (anaphase-promoting complex/cyclosome) composed
of eight protein subunits. As shown in Supplementary Fig. S4,
in vivo coimmunoprecipitation experiments revealed that GST-
Hip2 does not interact with cdc27 in the presence of endogenous
cyclin B1, suggesting that Hip2 is not a subunit of APC/C.
After conﬁrming the interaction between Hip2 and cyclin B1,
the potential role of Hip2 in the degradation of cyclin B1 through
the proteasome pathway was examined by performing in vivo
ubiquitination assays. HCT116 cells were transfected with con-
structs containing either pcDNA/HA-Hip2 or pcDNA/HA-Hip2
(S86Y), and pcDNA/Xpress-Ub. Hip2 (S86Y) is a Hip2 mutant that
lacks ubiquitin-conjugating activity. After 36 h, the cells were trea-
ted with the proteasome inhibitor MG-132 for an additional 5 h.
The cell extracts were immunoprecipitated with anti-cyclin B1
antibodies and then analyzed by immunoblotting with anti-Ub
antibodies. As shown in Fig 3A, ubiquitinated cyclin B1 proteins
were observed in cells overexpressing Hip2, but their level was sig-
niﬁcantly decreased in both control and in the Hip2 (S86Y) mutant.
To investigate the effect of Hip2 depletion on the ubiquitination
of cyclin B1, the RNAi technique was used to knock down Hip2
expression. The shRNA Hip2 expression vector and pcDNA/
Xpress-Ub were transiently co-transfected into HCT116 cells and
in vivo ubiquitination assays were conducted. The levels of ubiqui-
tinated cyclin B1 were dramatically decreased when Hip2 expres-
sion was knocked down in the cells (Fig. 3B). We further
investigated whether proteasomal inhibition rescues Hip2-medi-
ated cyclin B1 destabilization. HEK293 cells were transfected with
pcDNA/HA-Hip2 or a negative control vector. The cells were trea-
ted with or without the proteasome inhibitor MG-132. As showed
in Supplementary Fig. S5, proteasomal inhibition induced accumu-
lation of cyclin B1. Taken together, these results demonstrate that
Hip2 interacts with and degrades the cyclin B1 protein through the
ubiquitin proteasome pathway.
3.3. Hip2 antagonizes the apoptotic activity of cyclin B1
Based on previous reports showing that the overexpression of
cyclin B1 induces apoptosis [18], the effect of Hip2 on the regula-
tion of apoptosis by cyclin B1 was investigated. HCT116 cells were
transiently co-transfected with pcDNA/HisC-cyclin B1 and pcDNA/
HA-Hip2 (1:1) as shown in Fig. 4. At 48 h after transfection, the
cells were lysed and prepared for immunoblot analysis. The levels
Fig. 3. Hip2 ubiquitinates the cyclin B1 protein. (A) HCT116 cells were transiently co-transfected with pcDNA/HA-Hip2 or pcDNA/HA-Hip2 (S86Y), and pcDNA/Xpress-Ub.
After 36 h, the cells were incubated with 10 lMMG-132 for an additional 5 h. The cells lysates were immunoprecipitated with anti-cyclin B1 antibodies and bound proteins
were analyzed by immunoblotting against anti-ubiquitin antibodies. (B) HCT116 cells were transfected with either control shRNA or Hip2 shRNA, and pcDNA/Xpress-Ub.
After 36 h, the cells were incubated with 10 lMMG-132 for an additional 5 hr, and cell lysates were immunoprecipitated and analyzed as described in (A). (C) The efﬁciency
of Hip2 knock down was analyzed by probing against Hip2 antibodies.
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and, as expected, the overexpression of cyclin B1 increased the
amount of cleaved PARP. However, the amount of cleaved PARP
was dramatically decreased when cyclin B1 was co-expressed with
Hip-2. The levels of proapoptotic Bax and anti-apoptotic Bcl-2,
which regulate apoptosis at the mitochondrial level, were also
examined and quantitated. Cyclin B1 expression caused an in-
crease in the levels of Bax, and this effect was reversed by Hip2.
However, Bcl-2 levels were decreased during the expression of cy-
clin B1 alone, while Bcl-2 levels were increased when cyclin B1 was
co-expressed with Hip2 (Fig. 4A).
To further conﬁrm the effect of Hip2 on the regulation of apop-
tosis induced by cyclin B1, shRNA experiments were performed to
knock down Hip2 (Fig. 4B). HCT116 cells were transiently transfec-
ted with pcDNA/HisC-cyclin B1 and either Hip2 shRNA or control
shRNA. The efﬁciency of Hip2 knock down was conﬁrmed by prob-
ing with anti-Hip2 antibodies (Fig. 4C). The levels of cleaved PARP
were determined by immunoblot analysis. The amount of cleaved
PARP was increased in cells depleted of the Hip2 protein (Fig. 4B).
To examine the effect of Hip2 on cell viability, HCT116 cells
were transiently transfected with either pcDNA/HisC-cyclin B1 orpcDNA/HisC-cyclin B1, and pcDNA/HA-Hip2 (1:1), and 48 h after
transfection, the cells were assessed by trypan blue dye exclusion
assays. The overexpression of cyclin B1 dramatically decreased cell
viability and Hip2 prevented cyclin B1-induced cell death (Fig. 4D).
Cell death was next analyzed using FACS. HCT116 cells were
transiently transfected with pcDNA/HisC-cyclin B1 or pcDNA/
HisC-cyclin B1 and pcDNA/HA-Hip2 (1:1). Annexin V staining
was carried out, as plasma membrane phosphatidylserine (PS) is
translocated from the inner to the outer plasma membrane after
the induction of apoptosis [19]. As shown in Fig 4E, overexpression
of cyclin B1 increased the number of annexin V-stained apoptotic
cells compared to control and Hip2 co-expressing cells (Fig. 4E).
The results of the present study indicate that the ubiquitin-con-
jugating enzyme Hip2 interacts with cyclin B1 and promotes its
proteasomal-mediated degradation. Co-expression of Hip2 and cy-
clin B1 signiﬁcantly blocks cell death, suggesting that Hip2 could
be involved in the regulation of cyclin B1-mediated apoptosis.
The ubiquitin proteasome system is involved in cellular proteol-
ysis in eukaryotic cells and employs a series of three enzymes, E1,
E2, and E3 [8]. E3 ubiquitin ligase couples with E2 to bind and then
ubiquitinate substrate proteins, and the ubiquitinated substrates
Fig. 4. Hip2 antagonizes the apoptotic activity of cyclin B1. (A) HCT116 cells were transiently transfected with pcDNA/HA-Hip2, or pcDNA/HA-Hip2 and pcDNA/HisC–cyclin
B1. At 48 h after transfection, the cells were harvested, separated by 10% SDS–PAGE, and subjected to immunoblot analysis. PARP cleavage was analyzed by probing against
polyclonal anti-PARP antibodies. The membrane was subsequently probed against the following antibodies: Bax, Bcl-2, HA, His and actin as a loading control. The graph of the
bottom panel was quantiﬁed by the immunoblot results shown in the top panel. *P < 0.05 versus the control (student’s t-test) (B) HCT116 cells were transiently transfected
with control shRNA or Hip2 shRNA, and pcDNA/HisC–cyclin B1. After 36 h, the cells were harvested under the same conditions as in (A) and lysates were subjected to
immunoblot analysis with polyclonal anti-PARP antibodies. The membrane was subsequently probed with anti-His and anti–actin antibodies. (C) The efﬁciency of Hip2 knock
down was detected by probing with Hip2 antibodies. (D) The viability of HCT116 cells co-transfected with pcDNA/HA-Hip2, or pcDNA/HA-Hip2 and pcDNA/HisC–cyclin B1
(1:1), was analyzed by the trypan blue exclusion method. Experiments were repeated three times. (E) Apoptotic cells were detected by using the annexin V and propidium
iodide double staining method.
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ent study, we have not identiﬁed E3s that are cognated with Hip2,
a ubiquitin-conjugation enzyme, in the cyclin B1 degradation. It
was previously reported that Hip-2 seems to be able to play a role
as an E2 ubiquitin-conjugating enzyme in the absence of any E3
ligases [20]. Thus, cyclin B1 also might be degraded by Hip2 in
the absence of E3s. However, further studies are required to deter-
mine whether Hip2 mediates its effects in an E3-independent man-
ner or not.
Very recently, we reported that Hip2 signiﬁcantly blocked cell
death induced by staurosporine and Smac [16]. The present study
also revealed that Hip2 blocked cell death induced by the cyclin B1
protein. Based on these results, we speculate that during the apop-
totic process of a damaged cell, Hip2 might regulate Smac and cy-
clin B1 as follows. In response to apoptotic stimuli, Smac is
released into cytosol and inhibits the binding of IAPs to caspases,
enhancing apoptosis. Cyclin B1 accumulates in the cells and the in-
creased proteins block mitotic exit and promotes apoptosis. When
apoptotic stimuli are vanished, both Smac and cyclin B1 proteins
are degraded by ubiquitin–proteasome process including Hip2,
which promotes cell survival. Further studies are required to better
understand the detailed mechanisms of Hip2 function in the regu-
lation of apoptosis.Acknowledgements
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